All doses of the diabetes and weight management injectable tirzepatide (Mounjaro, Zepbound) were taken off the FDA's shortage ...

The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide, from its ...

Mounjaro, the brand name for tirzepatide, is a drug that treats type 2 diabetes by lowering blood sugar levels. According to ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

In this randomized controlled trial, in patients with both moderate-severe obstructive sleep apnea (OSA) and obesity, it was ...

The FDA has agreed to revisit its decision to prevent compounders from selling versions of Eli Lilly's diabetes and weight ...

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

With the resolution, compounding pharmacies are no longer able to produce tirzepatide. And the FDA highlighted the point to ...

These drugs work similarly but differ in dosage and specific indications (uses). Research suggests that tirzepatide is more ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

Lilly has earmarked $200 million for the upgrade, a company spokesperson confirmed to Fierce Pharma. The new project will ...

The FDA has decided to reconsider its previous decision that barred drug compounders from selling their versions of Eli Lilly ...